The global market for Ultra Long Acting Insulin was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ultra Long Acting Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ultra Long Acting Insulin.

The Ultra Long Acting Insulin market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ultra Long Acting Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Ultra Long Acting Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Ultra Long Acting Insulin Market Report

Report Metric	Details
Report Name	Ultra Long Acting Insulin Market
CAGR	5%
Segment by Type	Insulin Glargine Insulin Detemir Tresiba
Segment by Application	Type 1 Diabetes Type 2 Diabetes Gestational Diabetes
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi, Eli Lilly, Viatris, Gan&Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories International, Novo Nordisk, MNKD, Bristol-Myers Squibb Company, Emisphere, Biocon
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ultra Long Acting Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ultra Long Acting Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Ultra Long Acting Insulin Market report?

Ans: The main players in the Ultra Long Acting Insulin Market are Sanofi, Eli Lilly, Viatris, Gan&Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories International, Novo Nordisk, MNKD, Bristol-Myers Squibb Company, Emisphere, Biocon

What are the Application segmentation covered in the Ultra Long Acting Insulin Market report?

Ans: The Applications covered in the Ultra Long Acting Insulin Market report are Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes

What are the Type segmentation covered in the Ultra Long Acting Insulin Market report?

Ans: The Types covered in the Ultra Long Acting Insulin Market report are Insulin Glargine, Insulin Detemir, Tresiba

1 Ultra Long Acting Insulin Market Overview

1.1 Product Definition

1.2 Ultra Long Acting Insulin by Type

1.2.1 Global Ultra Long Acting Insulin Market Value Comparison by Type (2024 VS 2031)

1.2.2 Insulin Glargine

1.2.3 Insulin Detemir

1.2.4 Tresiba

1.3 Ultra Long Acting Insulin by Application

1.3.1 Global Ultra Long Acting Insulin Market Value by Application (2024 VS 2031)

1.3.2 Type 1 Diabetes

1.3.3 Type 2 Diabetes

1.3.4 Gestational Diabetes

1.4 Global Ultra Long Acting Insulin Market Size Estimates and Forecasts

1.4.1 Global Ultra Long Acting Insulin Revenue 2020-2031

1.4.2 Global Ultra Long Acting Insulin Sales 2020-2031

1.4.3 Global Ultra Long Acting Insulin Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Ultra Long Acting Insulin Market Competition by Manufacturers

2.1 Global Ultra Long Acting Insulin Sales Market Share by Manufacturers (2020-2025)

2.2 Global Ultra Long Acting Insulin Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Ultra Long Acting Insulin Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Ultra Long Acting Insulin, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Ultra Long Acting Insulin, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Ultra Long Acting Insulin, Product Type & Application

2.7 Global Key Manufacturers of Ultra Long Acting Insulin, Date of Enter into This Industry

2.8 Global Ultra Long Acting Insulin Market Competitive Situation and Trends

2.8.1 Global Ultra Long Acting Insulin Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Ultra Long Acting Insulin Players Market Share by Revenue

2.8.3 Global Ultra Long Acting Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Ultra Long Acting Insulin Market Scenario by Region

3.1 Global Ultra Long Acting Insulin Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Ultra Long Acting Insulin Sales by Region: 2020-2031

3.2.1 Global Ultra Long Acting Insulin Sales by Region: 2020-2025

3.2.2 Global Ultra Long Acting Insulin Sales by Region: 2026-2031

3.3 Global Ultra Long Acting Insulin Revenue by Region: 2020-2031

3.3.1 Global Ultra Long Acting Insulin Revenue by Region: 2020-2025

3.3.2 Global Ultra Long Acting Insulin Revenue by Region: 2026-2031

3.4 North America Ultra Long Acting Insulin Market Facts & Figures by Country

3.4.1 North America Ultra Long Acting Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Ultra Long Acting Insulin Sales by Country (2020-2031)

3.4.3 North America Ultra Long Acting Insulin Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Ultra Long Acting Insulin Market Facts & Figures by Country

3.5.1 Europe Ultra Long Acting Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Ultra Long Acting Insulin Sales by Country (2020-2031)

3.5.3 Europe Ultra Long Acting Insulin Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Ultra Long Acting Insulin Market Facts & Figures by Region

3.6.1 Asia Pacific Ultra Long Acting Insulin Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Ultra Long Acting Insulin Sales by Region (2020-2031)

3.6.3 Asia Pacific Ultra Long Acting Insulin Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Ultra Long Acting Insulin Market Facts & Figures by Country

3.7.1 Latin America Ultra Long Acting Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Ultra Long Acting Insulin Sales by Country (2020-2031)

3.7.3 Latin America Ultra Long Acting Insulin Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Ultra Long Acting Insulin Market Facts & Figures by Country

3.8.1 Middle East and Africa Ultra Long Acting Insulin Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Ultra Long Acting Insulin Sales by Country (2020-2031)

3.8.3 Middle East and Africa Ultra Long Acting Insulin Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Ultra Long Acting Insulin Sales by Type (2020-2031)

4.1.1 Global Ultra Long Acting Insulin Sales by Type (2020-2025)

4.1.2 Global Ultra Long Acting Insulin Sales by Type (2026-2031)

4.1.3 Global Ultra Long Acting Insulin Sales Market Share by Type (2020-2031)

4.2 Global Ultra Long Acting Insulin Revenue by Type (2020-2031)

4.2.1 Global Ultra Long Acting Insulin Revenue by Type (2020-2025)

4.2.2 Global Ultra Long Acting Insulin Revenue by Type (2026-2031)

4.2.3 Global Ultra Long Acting Insulin Revenue Market Share by Type (2020-2031)

4.3 Global Ultra Long Acting Insulin Price by Type (2020-2031)

5 Segment by Application

5.1 Global Ultra Long Acting Insulin Sales by Application (2020-2031)

5.1.1 Global Ultra Long Acting Insulin Sales by Application (2020-2025)

5.1.2 Global Ultra Long Acting Insulin Sales by Application (2026-2031)

5.1.3 Global Ultra Long Acting Insulin Sales Market Share by Application (2020-2031)

5.2 Global Ultra Long Acting Insulin Revenue by Application (2020-2031)

5.2.1 Global Ultra Long Acting Insulin Revenue by Application (2020-2025)

5.2.2 Global Ultra Long Acting Insulin Revenue by Application (2026-2031)

5.2.3 Global Ultra Long Acting Insulin Revenue Market Share by Application (2020-2031)

5.3 Global Ultra Long Acting Insulin Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Sanofi

6.1.1 Sanofi Company Information

6.1.2 Sanofi Description and Business Overview

6.1.3 Sanofi Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Sanofi Ultra Long Acting Insulin Product Portfolio

6.1.5 Sanofi Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Eli Lilly Ultra Long Acting Insulin Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 Viatris

6.3.1 Viatris Company Information

6.3.2 Viatris Description and Business Overview

6.3.3 Viatris Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Viatris Ultra Long Acting Insulin Product Portfolio

6.3.5 Viatris Recent Developments/Updates

6.4 Gan&Lee Pharmaceuticals

6.4.1 Gan&Lee Pharmaceuticals Company Information

6.4.2 Gan&Lee Pharmaceuticals Description and Business Overview

6.4.3 Gan&Lee Pharmaceuticals Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Gan&Lee Pharmaceuticals Ultra Long Acting Insulin Product Portfolio

6.4.5 Gan&Lee Pharmaceuticals Recent Developments/Updates

6.5 Tonghua Dongbao Pharmaceutical

6.5.1 Tonghua Dongbao Pharmaceutical Company Information

6.5.2 Tonghua Dongbao Pharmaceutical Description and Business Overview

6.5.3 Tonghua Dongbao Pharmaceutical Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Tonghua Dongbao Pharmaceutical Ultra Long Acting Insulin Product Portfolio

6.5.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates

6.6 United Laboratories International

6.6.1 United Laboratories International Company Information

6.6.2 United Laboratories International Description and Business Overview

6.6.3 United Laboratories International Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.6.4 United Laboratories International Ultra Long Acting Insulin Product Portfolio

6.6.5 United Laboratories International Recent Developments/Updates

6.7 Novo Nordisk

6.7.1 Novo Nordisk Company Information

6.7.2 Novo Nordisk Description and Business Overview

6.7.3 Novo Nordisk Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Novo Nordisk Ultra Long Acting Insulin Product Portfolio

6.7.5 Novo Nordisk Recent Developments/Updates

6.8 MNKD

6.8.1 MNKD Company Information

6.8.2 MNKD Description and Business Overview

6.8.3 MNKD Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.8.4 MNKD Ultra Long Acting Insulin Product Portfolio

6.8.5 MNKD Recent Developments/Updates

6.9 Bristol-Myers Squibb Company

6.9.1 Bristol-Myers Squibb Company Company Information

6.9.2 Bristol-Myers Squibb Company Description and Business Overview

6.9.3 Bristol-Myers Squibb Company Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Bristol-Myers Squibb Company Ultra Long Acting Insulin Product Portfolio

6.9.5 Bristol-Myers Squibb Company Recent Developments/Updates

6.10 Emisphere

6.10.1 Emisphere Company Information

6.10.2 Emisphere Description and Business Overview

6.10.3 Emisphere Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Emisphere Ultra Long Acting Insulin Product Portfolio

6.10.5 Emisphere Recent Developments/Updates

6.11 Biocon

6.11.1 Biocon Company Information

6.11.2 Biocon Description and Business Overview

6.11.3 Biocon Ultra Long Acting Insulin Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Biocon Ultra Long Acting Insulin Product Portfolio

6.11.5 Biocon Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Ultra Long Acting Insulin Industry Chain Analysis

7.2 Ultra Long Acting Insulin Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Ultra Long Acting Insulin Production Mode & Process Analysis

7.4 Ultra Long Acting Insulin Sales and Marketing

7.4.1 Ultra Long Acting Insulin Sales Channels

7.4.2 Ultra Long Acting Insulin Distributors

7.5 Ultra Long Acting Insulin Customer Analysis

8 Ultra Long Acting Insulin Market Dynamics

8.1 Ultra Long Acting Insulin Industry Trends

8.2 Ultra Long Acting Insulin Market Drivers

8.3 Ultra Long Acting Insulin Market Challenges

8.4 Ultra Long Acting Insulin Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sanofi

Eli Lilly

Viatris

Gan & Lee Pharmaceuticals

Tonghua Dongbao Pharmaceutical

Novo Nordisk

MNKD

Bristol Myers Squibb Company

Emisphere

Biocon Ltd.

United Laboratories International

List of Tables

Table 1. Global Ultra Long Acting Insulin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Ultra Long Acting Insulin Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Ultra Long Acting Insulin Market Competitive Situation by Manufacturers in 2024

Table 4. Global Ultra Long Acting Insulin Sales (Tons) of Key Manufacturers (2020-2025)

Table 5. Global Ultra Long Acting Insulin Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Ultra Long Acting Insulin Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Ultra Long Acting Insulin Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Ultra Long Acting Insulin Average Price (US$/Ton) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Ultra Long Acting Insulin, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Ultra Long Acting Insulin, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Ultra Long Acting Insulin, Product Type & Application

Table 12. Global Key Manufacturers of Ultra Long Acting Insulin, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Ultra Long Acting Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ultra Long Acting Insulin as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Ultra Long Acting Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Ultra Long Acting Insulin Sales by Region (2020-2025) & (Tons)

Table 18. Global Ultra Long Acting Insulin Sales Market Share by Region (2020-2025)

Table 19. Global Ultra Long Acting Insulin Sales by Region (2026-2031) & (Tons)

Table 20. Global Ultra Long Acting Insulin Sales Market Share by Region (2026-2031)

Table 21. Global Ultra Long Acting Insulin Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Ultra Long Acting Insulin Revenue Market Share by Region (2020-2025)

Table 23. Global Ultra Long Acting Insulin Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Ultra Long Acting Insulin Revenue Market Share by Region (2026-2031)

Table 25. North America Ultra Long Acting Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Ultra Long Acting Insulin Sales by Country (2020-2025) & (Tons)

Table 27. North America Ultra Long Acting Insulin Sales by Country (2026-2031) & (Tons)

Table 28. North America Ultra Long Acting Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Ultra Long Acting Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Ultra Long Acting Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Ultra Long Acting Insulin Sales by Country (2020-2025) & (Tons)

Table 32. Europe Ultra Long Acting Insulin Sales by Country (2026-2031) & (Tons)

Table 33. Europe Ultra Long Acting Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Ultra Long Acting Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Ultra Long Acting Insulin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Ultra Long Acting Insulin Sales by Region (2020-2025) & (Tons)

Table 37. Asia Pacific Ultra Long Acting Insulin Sales by Region (2026-2031) & (Tons)

Table 38. Asia Pacific Ultra Long Acting Insulin Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Ultra Long Acting Insulin Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Ultra Long Acting Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Ultra Long Acting Insulin Sales by Country (2020-2025) & (Tons)

Table 42. Latin America Ultra Long Acting Insulin Sales by Country (2026-2031) & (Tons)

Table 43. Latin America Ultra Long Acting Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Ultra Long Acting Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Ultra Long Acting Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Ultra Long Acting Insulin Sales by Country (2020-2025) & (Tons)

Table 47. Middle East and Africa Ultra Long Acting Insulin Sales by Country (2026-2031) & (Tons)

Table 48. Middle East and Africa Ultra Long Acting Insulin Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Ultra Long Acting Insulin Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Ultra Long Acting Insulin Sales (Tons) by Type (2020-2025)

Table 51. Global Ultra Long Acting Insulin Sales (Tons) by Type (2026-2031)

Table 52. Global Ultra Long Acting Insulin Sales Market Share by Type (2020-2025)

Table 53. Global Ultra Long Acting Insulin Sales Market Share by Type (2026-2031)

Table 54. Global Ultra Long Acting Insulin Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Ultra Long Acting Insulin Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Ultra Long Acting Insulin Revenue Market Share by Type (2020-2025)

Table 57. Global Ultra Long Acting Insulin Revenue Market Share by Type (2026-2031)

Table 58. Global Ultra Long Acting Insulin Price (US$/Ton) by Type (2020-2025)

Table 59. Global Ultra Long Acting Insulin Price (US$/Ton) by Type (2026-2031)

Table 60. Global Ultra Long Acting Insulin Sales (Tons) by Application (2020-2025)

Table 61. Global Ultra Long Acting Insulin Sales (Tons) by Application (2026-2031)

Table 62. Global Ultra Long Acting Insulin Sales Market Share by Application (2020-2025)

Table 63. Global Ultra Long Acting Insulin Sales Market Share by Application (2026-2031)

Table 64. Global Ultra Long Acting Insulin Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Ultra Long Acting Insulin Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Ultra Long Acting Insulin Revenue Market Share by Application (2020-2025)

Table 67. Global Ultra Long Acting Insulin Revenue Market Share by Application (2026-2031)

Table 68. Global Ultra Long Acting Insulin Price (US$/Ton) by Application (2020-2025)

Table 69. Global Ultra Long Acting Insulin Price (US$/Ton) by Application (2026-2031)

Table 70. Sanofi Company Information

Table 71. Sanofi Description and Business Overview

Table 72. Sanofi Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 73. Sanofi Ultra Long Acting Insulin Product

Table 74. Sanofi Recent Developments/Updates

Table 75. Eli Lilly Company Information

Table 76. Eli Lilly Description and Business Overview

Table 77. Eli Lilly Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 78. Eli Lilly Ultra Long Acting Insulin Product

Table 79. Eli Lilly Recent Developments/Updates

Table 80. Viatris Company Information

Table 81. Viatris Description and Business Overview

Table 82. Viatris Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 83. Viatris Ultra Long Acting Insulin Product

Table 84. Viatris Recent Developments/Updates

Table 85. Gan&Lee Pharmaceuticals Company Information

Table 86. Gan&Lee Pharmaceuticals Description and Business Overview

Table 87. Gan&Lee Pharmaceuticals Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 88. Gan&Lee Pharmaceuticals Ultra Long Acting Insulin Product

Table 89. Gan&Lee Pharmaceuticals Recent Developments/Updates

Table 90. Tonghua Dongbao Pharmaceutical Company Information

Table 91. Tonghua Dongbao Pharmaceutical Description and Business Overview

Table 92. Tonghua Dongbao Pharmaceutical Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 93. Tonghua Dongbao Pharmaceutical Ultra Long Acting Insulin Product

Table 94. Tonghua Dongbao Pharmaceutical Recent Developments/Updates

Table 95. United Laboratories International Company Information

Table 96. United Laboratories International Description and Business Overview

Table 97. United Laboratories International Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 98. United Laboratories International Ultra Long Acting Insulin Product

Table 99. United Laboratories International Recent Developments/Updates

Table 100. Novo Nordisk Company Information

Table 101. Novo Nordisk Description and Business Overview

Table 102. Novo Nordisk Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 103. Novo Nordisk Ultra Long Acting Insulin Product

Table 104. Novo Nordisk Recent Developments/Updates

Table 105. MNKD Company Information

Table 106. MNKD Description and Business Overview

Table 107. MNKD Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 108. MNKD Ultra Long Acting Insulin Product

Table 109. MNKD Recent Developments/Updates

Table 110. Bristol-Myers Squibb Company Company Information

Table 111. Bristol-Myers Squibb Company Description and Business Overview

Table 112. Bristol-Myers Squibb Company Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 113. Bristol-Myers Squibb Company Ultra Long Acting Insulin Product

Table 114. Bristol-Myers Squibb Company Recent Developments/Updates

Table 115. Emisphere Company Information

Table 116. Emisphere Description and Business Overview

Table 117. Emisphere Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 118. Emisphere Ultra Long Acting Insulin Product

Table 119. Emisphere Recent Developments/Updates

Table 120. Biocon Company Information

Table 121. Biocon Description and Business Overview

Table 122. Biocon Ultra Long Acting Insulin Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)

Table 123. Biocon Ultra Long Acting Insulin Product

Table 124. Biocon Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Ultra Long Acting Insulin Distributors List

Table 128. Ultra Long Acting Insulin Customers List

Table 129. Ultra Long Acting Insulin Market Trends

Table 130. Ultra Long Acting Insulin Market Drivers

Table 131. Ultra Long Acting Insulin Market Challenges

Table 132. Ultra Long Acting Insulin Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Ultra Long Acting Insulin

Figure 2. Global Ultra Long Acting Insulin Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Ultra Long Acting Insulin Market Share by Type: 2024 & 2031

Figure 4. Insulin Glargine Product Picture

Figure 5. Insulin Detemir Product Picture

Figure 6. Tresiba Product Picture

Figure 7. Global Ultra Long Acting Insulin Market Value by Application (2020-2031) & (US$ Million)

Figure 8. Global Ultra Long Acting Insulin Market Share by Application: 2024 & 2031

Figure 9. Type 1 Diabetes

Figure 10. Type 2 Diabetes

Figure 11. Gestational Diabetes

Figure 12. Global Ultra Long Acting Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Ultra Long Acting Insulin Market Size (2020-2031) & (US$ Million)

Figure 14. Global Ultra Long Acting Insulin Sales (2020-2031) & (Tons)

Figure 15. Global Ultra Long Acting Insulin Average Price (US$/Ton) & (2020-2031)

Figure 16. Ultra Long Acting Insulin Report Years Considered

Figure 17. Ultra Long Acting Insulin Sales Share by Manufacturers in 2024

Figure 18. Global Ultra Long Acting Insulin Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Ultra Long Acting Insulin Players: Market Share by Revenue in Ultra Long Acting Insulin in 2024

Figure 20. Ultra Long Acting Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Ultra Long Acting Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Ultra Long Acting Insulin Sales Market Share by Country (2020-2031)

Figure 23. North America Ultra Long Acting Insulin Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Ultra Long Acting Insulin Sales Market Share by Country (2020-2031)

Figure 27. Europe Ultra Long Acting Insulin Revenue Market Share by Country (2020-2031)

Figure 28. Germany Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Ultra Long Acting Insulin Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Ultra Long Acting Insulin Revenue Market Share by Region (2020-2031)

Figure 35. China Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. China Taiwan Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Southeast Asia Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Latin America Ultra Long Acting Insulin Sales Market Share by Country (2020-2031)

Figure 43. Latin America Ultra Long Acting Insulin Revenue Market Share by Country (2020-2031)

Figure 44. Mexico Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Brazil Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Argentina Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Middle East and Africa Ultra Long Acting Insulin Sales Market Share by Country (2020-2031)

Figure 48. Middle East and Africa Ultra Long Acting Insulin Revenue Market Share by Country (2020-2031)

Figure 49. Turkey Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. UAE Ultra Long Acting Insulin Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Global Sales Market Share of Ultra Long Acting Insulin by Type (2020-2031)

Figure 53. Global Revenue Market Share of Ultra Long Acting Insulin by Type (2020-2031)

Figure 54. Global Ultra Long Acting Insulin Price (US$/Ton) by Type (2020-2031)

Figure 55. Global Sales Market Share of Ultra Long Acting Insulin by Application (2020-2031)

Figure 56. Global Revenue Market Share of Ultra Long Acting Insulin by Application (2020-2031)

Figure 57. Global Ultra Long Acting Insulin Price (US$/Ton) by Application (2020-2031)

Figure 58. Ultra Long Acting Insulin Value Chain

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions